Repare Therapeutics (NASDAQ:RPTX) Rating Increased to Buy at Bloom Burton

Repare Therapeutics (NASDAQ:RPTX) was upgraded by equities researchers at Bloom Burton from an “accumulate” rating to a “buy” rating in a research note issued on Friday, Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a report on Wednesday, February 21st.

Repare Therapeutics Stock Performance

Shares of Repare Therapeutics stock opened at $3.15 on Friday. Repare Therapeutics has a 1 year low of $2.98 and a 1 year high of $13.85. The company has a market capitalization of $116.55 million, a P/E ratio of -1.41 and a beta of 0.56. The company’s fifty day moving average is $5.30 and its two-hundred day moving average is $5.73.

Repare Therapeutics (NASDAQ:RPTX) last issued its earnings results on Wednesday, February 28th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.11). The firm had revenue of $13.05 million during the quarter, compared to analysts’ expectations of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative return on equity of 39.82%. As a group, equities analysts expect that Repare Therapeutics will post -2.74 earnings per share for the current year.

Hedge Funds Weigh In On Repare Therapeutics

Institutional investors have recently modified their holdings of the company. Deutsche Bank AG acquired a new position in shares of Repare Therapeutics in the fourth quarter valued at approximately $40,000. Wells Fargo & Company MN raised its position in shares of Repare Therapeutics by 185.8% in the fourth quarter. Wells Fargo & Company MN now owns 3,041 shares of the company’s stock valued at $45,000 after buying an additional 1,977 shares during the last quarter. Barclays PLC purchased a new stake in Repare Therapeutics in the second quarter valued at approximately $36,000. UBS Group AG grew its holdings in Repare Therapeutics by 26.3% in the third quarter. UBS Group AG now owns 3,551 shares of the company’s stock valued at $43,000 after purchasing an additional 739 shares during the period. Finally, SRS Capital Advisors Inc. purchased a new stake in Repare Therapeutics in the first quarter valued at approximately $49,000. Institutional investors and hedge funds own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.